These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Martinez-Lado L; Calviño-Díaz C; Piñeiro A; Dierssen T; Vazquez-Rodriguez TR; Miranda-Filloy JA; Lopez-Diaz MJ; Blanco R; Llorca J; Gonzalez-Gay MA Medicine (Baltimore); 2011 May; 90(3):186-193. PubMed ID: 21512412 [TBL] [Abstract][Full Text] [Related]
5. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Alba MA; García-Martínez A; Prieto-González S; Tavera-Bahillo I; Corbera-Bellalta M; Planas-Rigol E; Espígol-Frigolé G; Butjosa M; Hernández-Rodríguez J; Cid MC Medicine (Baltimore); 2014 Jul; 93(5):194-201. PubMed ID: 25181312 [TBL] [Abstract][Full Text] [Related]
6. Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases. Boiardi L; Galli E; Macchioni P; Muratore F; Klinowski G; Hunder GG; Casali M; Besutti G; Spaggiari L; Versari A; Croci S; Mancuso P; Rossi PG; Marvisi C; Salvarani C Semin Arthritis Rheum; 2023 Apr; 59():152173. PubMed ID: 36780709 [TBL] [Abstract][Full Text] [Related]
7. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. Jakobsson K; Jacobsson L; Mohammad AJ; Nilsson JÅ; Warrington K; Matteson EL; Turesson C BMC Musculoskelet Disord; 2016 Aug; 17(1):363. PubMed ID: 27558589 [TBL] [Abstract][Full Text] [Related]
8. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122 [TBL] [Abstract][Full Text] [Related]
13. Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. Macchioni P; Boiardi L; Muratore F; Restuccia G; Cavazza A; Pipitone N; Catanoso M; Mancuso P; Luberto F; Giorgi Rossi P; Salvarani C Rheumatology (Oxford); 2019 Apr; 58(4):609-616. PubMed ID: 30517710 [TBL] [Abstract][Full Text] [Related]
14. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437 [TBL] [Abstract][Full Text] [Related]
15. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Hernández-Rodríguez J; García-Martínez A; Casademont J; Filella X; Esteban MJ; López-Soto A; Fernández-Solà J; Urbano-Márquez A; Grau JM; Cid MC Arthritis Rheum; 2002 Feb; 47(1):29-35. PubMed ID: 11932875 [TBL] [Abstract][Full Text] [Related]
16. Giant cell arteritis: a multicenter observational study in Brazil. Souza AW; Okamoto KY; Abrantes F; Schau B; Bacchiega AB; Shinjo SK Clinics (Sao Paulo); 2013; 68(3):317-22. PubMed ID: 23644850 [TBL] [Abstract][Full Text] [Related]
17. The U.S. Veterans Health Administration national giant cell arteritis (GCA) database cohort: incident ophthalmic complications in biopsy-negative GCA patients. Chung SH; Morcos MB; Pollock PS; Ng B Clin Rheumatol; 2021 Jul; 40(7):2829-2833. PubMed ID: 33417014 [TBL] [Abstract][Full Text] [Related]